Interview with Dr. Ken Culver, ALK Positive, Inc. Director of Research & Clinical Affairs

In only seven months as our Director of Research and Clinical Affairs, Dr. Ken Culver has made a tremendous impact with our organization. With over three decades of work in pediatrics, immunology, pharmaceutical drug development for cancer treatment, as well as laboratory research in 1990 that contributed to the first ever human gene therapy trial for the treatment of children with adenosine deaminase (ADA) deficiency. It's an inspiring interview with Ken - and we are fortunate to have him with us in a leadership position. Be Inspired!

ALK Positive News, ResearchKirk SmithMay 15, 2023Dr. Ken Culver, Director of Research and Clinical Affairs

Dr. Kenneth Culver named Director of Research & Clinical Affairs for ALK Positive, Inc.

We are excited to welcome Dr. Kenneth Culver as our first Director of Research & Clinical Affairs Dr. Culver worked for 20 years at Novartis Oncology where he contributed to the development of 12 compounds including ceritinib for ALK+ NSCLC. In his last role, he served as Head, US Thoracic Oncology Clinical Strategy and Lead for the Center of Excellence for Immuno-Oncology for US Clinical Development and Medical Affairs. Most recently, he was the Global Medical Affairs Leader for the Cell and Gene Oncology program at GlaxoSmithKline.

ALK Positive NewsKirk SmithSeptember 29, 2022Dr. Ken Culver, research